Amplifier is developing ATX-304 that promotes pan-AMPK activation as a first-in-class compound with unique properties
ATX-304 has been shown in cell-free systems and intact cells to activate AMPK and has shown beneficial metabolic and cardiovascular effects in pre-clinical models.
In early human trials with exposure up to 4 weeks, ATX-304 was found to be safe and well tolerated.
ATX-304 has multiple therapeutic applications in metabolic conditions and cardiovascular diseases.
Steneberg, P., et. al. JCI Insight. 2018. 3(12). e99114. DOI: 10.1172/jci.insight.99114.
Ericsson, M., et. al. Commun. Biol. 2021. 4(1306). DOI: 10.1038/s42003-021-02837-0.